Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC.

ABSTRACT:

Introduction

Metformin, a common medication used in the treatment of diabetes mellitus is known to have anticancer effects. We hypothesized that the salutary effect of metformin on the survival of patients with stage I NSCLC is influenced by body mass index (BMI).

Methods

Patients undergoing lobectomy for stage I NSCLC without neoadjuvant therapy were included. Univariate and multivariate survival analyses to examine the association between metformin use and overall survival (OS), disease-specific survival (DSS), and recurrence-free survival were performed, stratified by BMI (>25 kg/m² and ≤25 kg/m²). Expression of immune checkpoints in patients on metformin and not was performed in a separate cohort of 205 patients with advanced disease.

Results

SUBMITTER: Yendamuri S 

PROVIDER: S-EPMC7386563 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature